Kathleen Hayes

Founded in 1998, Outcome Sciences, Inc. (d/b/a Outcome) spun out of a Harvard affiliated research laboratory. The company has focused on outcomes studies since its inception and has dedicated itself to leading the way in registries, post-approval research, and quality improvement initiatives. The firm's world headquarters are located in Cambridge, MA and St-Prex, Switzerland and it has regional offices in Chicago, Washington DC, London, Mumbai, Tokyo, and Sydney. The firm has designed, developed, and managed an industry-leading number of patient registries and post-approval studies and have expertise and experience in more than 40 therapeutic areas. Its programs include thousands of sites and millions of patients across the globe. Outcome has program participants in more than 80 countries on 6 continents, with more than 2,500 U.S. hospitals participating in at least one Outcome registry. In addition to working with life sciences companies, it also partner with many providers and healthcare organizations, specialty associations, hospital associations, pharmacist associations, managed care organizations, state departments of public health, Quality Improvement Organizations (QIOs), and government agencies. In fact, nearly 2,000 healthcare organizations are its direct customers. Outcome regularly works with thought leaders, regulators, and government agencies from many regions of the world, including the European Medicines Agency, the Agency for Healthcare Research and Quality, the U.S. Food and Drug Administration, the UK National Institute for Health and Clinical Excellence, and many more.

ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA.